MA51073A - INHIBITION OF MUTANT HDI-1 - Google Patents

INHIBITION OF MUTANT HDI-1

Info

Publication number
MA51073A
MA51073A MA051073A MA51073A MA51073A MA 51073 A MA51073 A MA 51073A MA 051073 A MA051073 A MA 051073A MA 51073 A MA51073 A MA 51073A MA 51073 A MA51073 A MA 51073A
Authority
MA
Morocco
Prior art keywords
inhibition
hdi
mutant
mutant hdi
Prior art date
Application number
MA051073A
Other languages
French (fr)
Other versions
MA51073B1 (en
Inventor
Susan Ashwell
Alan Collis
Jeff Davis
Patrick F Kelly
Blythe Thomson
Duncan Walker
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Priority claimed from PCT/US2019/032747 external-priority patent/WO2019222553A1/en
Publication of MA51073A publication Critical patent/MA51073A/en
Publication of MA51073B1 publication Critical patent/MA51073B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA51073A 2018-05-16 2019-05-16 Mutant Idh-1 inhibition MA51073B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672461P 2018-05-16 2018-05-16
PCT/US2019/032747 WO2019222553A1 (en) 2018-05-16 2019-05-16 Inhibiting mutant idh-1

Publications (2)

Publication Number Publication Date
MA51073A true MA51073A (en) 2020-10-14
MA51073B1 MA51073B1 (en) 2023-04-28

Family

ID=86227080

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51073A MA51073B1 (en) 2018-05-16 2019-05-16 Mutant Idh-1 inhibition

Country Status (1)

Country Link
MA (1) MA51073B1 (en)

Also Published As

Publication number Publication date
MA51073B1 (en) 2023-04-28

Similar Documents

Publication Publication Date Title
MA44725A (en) LSD1 INHIBITOR FORMULATIONS
MA51066A (en) INHIBITORS OF INTEGRIN
MA51616A (en) DNA-PK INHIBITORS
MA52004A (en) O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS
MA54521A (en) SUBSTITUTED OXOPYRIDINE DERIVATIVES
MA51337A (en) SPIRO EXO-AZA INHIBITORS OF MENIN-MLL INTERACTION
MA49006A (en) IP6K INHIBITORS
MA53010A (en) FORMULATIONS OF AN AXL / MER INHIBITOR
EP3737757A4 (en) Methods of treatment by inhibition of bfl 1
MA39500A (en) COMPOSITIONS BASED ON PLANT EXTRACTS FOR THE INHIBITION OF 5-ALPHA-REDUCTASE
ES2980849T3 (en) Preparation of protected DO3A
MA52934A (en) OGA INHIBITOR COMPOUNDS
MA53648A (en) O-GLYCOPROTEIN-2-ACETAMIDO-2-DESOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
MA52298A (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS SELECTIVELY INHIBITING MYOSIN 2 ISOFORMS
ES1225190Y (en) SHOWER SET
MA43764A (en) MONOVALENT INHIBITOR OF THE HUTNFR1 INTERACTION
MA51073A (en) INHIBITION OF MUTANT HDI-1
MA54237A (en) ATTRACTIVE COMPOSITION OF THE SPECIES DELOTTOCOCCUS ABERIAE
MA53009A (en) ASK1 INHIBITORS
DK3720442T3 (en) INHIBITION OF MUTANT IDH-1
UA38485S (en) INTERIOR OF THE TRADE ESTABLISHMENT
UA39162S (en) INTERIOR OF THE TRADE ESTABLISHMENT
SG11202101817UA (en) Methods of inhibition
UA38273S (en) INTERIOR OF FOOD ESTABLISHMENT
UA38263S (en) INTERIOR OF FOOD ESTABLISHMENT